Roche lengthens Perjeta add-on evidence to six years

11 December 2019

Pharma giant Roche (ROG: SIX) and three not-for-profit partners have announced new long-term data in HER2-positive early breast cancer (eBC).

The Swiss company presented results from a second interim overall survival (OS) analysis of the Phase III APHINITY study, evaluating the addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and chemotherapy as an adjuvant treatment.

This latest interim OS analysis was conducted after a median follow-up of approximately 74 months, compared to around 45 months for the primary analysis in 2017, and includes updated descriptive invasive disease-free survival (iDFS) and cardiac safety data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK